semaglutide phase 3 In an interim analysis of a trial involving 800 patients with metabolic dysfunction–associated steatohepatitis, once-weekly improved liver histologic results at 72 weeks. Full ESSENCE trial results and Research Summary Three new phase 3 REIMAGINE

This ratio helps consumers understand how much protein they are receiving per calorie, enabling them to make choices that maximize protein intake while managing overall caloric load

Landmark trials include STEP (semaglutide for weight management, NEJM 2021), SURMOUNT (tirzepatide for weight management, NEJM 2022), and SURMOUNT-OSA (tirzepatide for obstructive sleep apnea, NEJM 2024)

Chief among those concerns are side effects, with 51% of respondents citing current side effects such as nausea, vomiting, headaches, and more as a top concern when it comes to GLP-1 medications, while 40% said they are worried about potential long-term side effects that may develop with use

This percentage helps prevent over-discharge and overcharge issues during extended periods of inactivity